title: RhoGDI2 confers resistance to 5-fluorouracil in human gastric cancer cells.
abstract: Resistance to 5-fluorouracil (5-FU) in patients with gastric cancer is a serious therapeutic problem and major efforts are underway to understand the underlying mechanisms. We have previously identified RhoGDI2 as a contributor to 5-FU resistance in colon cancer cells using 2D electrophoresis and mass spectrometry and the current study aimed to further investigate this role. The expression of RhoGDI2 in seven gastric cancer cell lines was positively correlated with resistance to 5-FU. Lower 5-FU sensitivity of isolated tumor cells from patients with gastric cancer was also associated with higher RhoGDI2 expression. Ectopic expression of RhoGDI2 in gastric cancer cells increased the resistance to 5-FU and reverted low dose 5-FU-induced G2/M phase arrest without affecting the population of sub-G1 cells. Overall, these findings suggest that RhoGDI2 is associated with 5-FU resistance and is a potential therapeutic target for enhancing chemotherapy efficacy in gastric cancer.
authors.affiliation: Department of Oncology, Fudan University Shanghai Cancer Center, Shanghai Medical College, Fudan University;
authors.forename: Zhong
authors.initials: Z
authors.lastname: Zheng
authors.forename: Xiang-Yi
authors.initials: XY
authors.lastname: He
authors.forename: Jian-Fang
authors.initials: JF
authors.lastname: Li
authors.forename: Bei-Qin
authors.initials: BQ
authors.lastname: Yu
authors.forename: Xue-Hua
authors.initials: XH
authors.lastname: Chen
authors.forename: Jun
authors.initials: J
authors.lastname: Ji
authors.forename: Jia-Nian
authors.initials: JN
authors.lastname: Zhang
authors.forename: Qin-Long
authors.initials: QL
authors.lastname: Gu
authors.forename: Zheng-Gang
authors.initials: ZG
authors.lastname: Zhu
authors.forename: Bing-Ya
authors.initials: BY
authors.lastname: Liu